Global Non Hodgkin Lymphoma NHL Market Report 2024

Non Hodgkin Lymphoma (NHL) Global Market Report 2024 – By Type (B-Cell Lymphoma, T-Cell Lymphoma), By Treatment (Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy), By Route of Administration (Oral, Parenteral, Other Routes of Administration), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels), By End-Users (Hospitals, Homecare, Specialty Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Non Hodgkin Lymphoma (NHL) Global Market Report 2023

Proud Members Of

checkslacipN checkaoirsN checkscipN

Non-Hodgkin lymphoma (NHL) Market Definition And Segments

Non-Hodgkin lymphoma is a cancer of the lymphatic system characterized by the abnormal growth of white blood cells. It is a form of cancer that develops in the immune system component of the body's lymphatic system, which is responsible for battling infection.

The main types of non-Hodgkin lymphoma (NHL) are B-cell lymphoma and T-cell lymphoma. B-cell lymphoma refers to a group of cancer that originate from abnormal B lymphocytes in the immune system. Non-Hodgkin lymphoma treatment for B-cell lymphomas typically involves a combination of therapies, such as chemotherapy, immunotherapy, targeted therapy, radiation therapy, and stem cell transplant. The various types of treatments are involved, including surgery, stem cell transplant, chemotherapy, immunotherapy, targeted therapy, and radiation therapy, which can be administered through various routes, including oral, parenteral, and others. These are sold through several distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used by various end-users, including hospitals, homecare facilities, specialty centers, and others.

The non-Hodgkin lymphoma (NHL) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

The non-Hodgkin lymphoma (NHL) market size has grown strongly in recent years. It will grow from $9.34 billion in 2023 to $10.23 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increased incidence of NHL, advancements in diagnostics, chemotherapy and immunotherapy, clinical research and drug development, improved survival rates.

The non-Hodgkin lymphoma (NHL) market size is expected to see strong growth in the next few years. It will grow to $14.13 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to growing aging population, advancements in targeted therapies, immunotherapy innovations, precision medicine approaches, increasing awareness and early detection. Major trends in the forecast period include rise of biosimilars, integration of next-generation sequencing, adoption of car-t cell therapies, novel chemotherapy agents, real-world evidence and outcomes research.

High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth

The high prevalence of non-Hodgkin lymphoma is expected to propel the growth of the non-Hodgkin lymphoma market going forward. It is a cancer that develops in the lymphatic system, which is part of your immune system. The prevalence of non-Hodgkin lymphoma refers to the number of individuals in a population who are currently diagnosed with or living with the condition at a specific time. Non-Hodgkin lymphoma treatment helps improve outcomes for individuals already diagnosed with the condition by targeting and managing the cancer cells. For instance, in January 2023, according to the American Cancer Society, a US-based cancer health organization, non-Hodgkin lymphoma accounts for 4% of all cancers, and in 2023, it will affect around 80,550 Americans, including 44,880 males and 35,670 females. It also estimates that 20,180 people will die in 2023 because of non-Hodgkin lymphoma. Furthermore, in May 2022, according to the Canadian Cancer Society, a Canada-based national cancer charity, non-Hodgkin lymphoma would be diagnosed in 11,400 Canadians in the year 2022. It would claim the lives of 3,000 Canadians. Therefore, the high prevalence of non-Hodgkin lymphoma is driving the non-Hodgkin lymphoma market.

Rising Disease Incidence In Older Adults Shaping NHL Market Growth

The rising geriatric population is expected to propel the growth of the non-Hodgkin lymphoma (NHL) market going forward. The geriatric population is the segment of the population that consists of older adults, typically defined as individuals who are 65 or older. The geriatric population has a higher incidence of the disease, emphasizing the importance of specialized care and treatment considerations for elderly individuals facing this hematological malignancy. For instance, in October 2022, according to the World Health Organization, a US-based specialized health agency, globally, 1 in 6 individuals would be 60 or older by 2030 and is expected to reach 2.1 billion elderly people by 2050. Therefore, the rising geriatric population is driving the growth of the non-Hodgkin lymphoma (NHL) market.

Major companies operating in the non-Hodgkin lymphoma (NHL) market report are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline PLC, AbbVie Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Bispecific Antibody Revolutionizes Treatment Options For Relapsed Lymphoma

Advancements in drug innovations are a key trend gaining popularity in the non-Hodgkin lymphoma market. Companies operating in the non-Hodgkin market are focused on innovating new products to sustain their position in the market. For instance, in December 2022, Genentech Inc., a US-based biotechnology company, received FDA approval for Lunsumio, a novel bispecific antibody for treating relapsed or refractory follicular lymphoma. This antibody is a new class of fixed-duration cancer treatment immunotherapy, and it is a readily available and off-the-shelf treatment option patients do not need to wait to receive this immunotherapy treatment. The FDA approval is based on positive results from the Lunsumio Phase II GO29781 research in persons with extensively pretreated FL, particularly those at high risk of illness progression or unresponsive to prior treatments.

Advancements In Non-Hodgkin Lymphoma Treatment

Major companies operating in the non-Hodgkin lymphoma market are increasing their focus on introducing advanced immunotherapies, such as Epcoritamab-bysp (EPKINLY), to gain a competitive edge in the market. Epcoritamab-bysp (EPKINLY) is an investigational subcutaneous immunotherapy designed to target CD20-expressing B-cell malignancies, showing promising results in clinical trials, particularly in relapsed or refractory B-cell non-Hodgkin lymphoma. For instance, in November 2023, AbbVie Inc., a US-based pharmaceutical company, received a breakthrough therapy designation (BTD) from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY). The approval was granted for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more therapies. Additionally, the European Medicines Agency (EMA) has validated a Type II application for epcoritamab (TEPKINLY) for the same indication. These updates were supported by previously announced results from the Phase 1/2 EPCORE NHL-1 clinical trial. The trial evaluated the safety and preliminary efficacy of subcutaneous epcoritamab in 128 adult patients with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL), including FL.

AstraZeneca Expands Oncology Portfolio With Acquisition Of Teneotwo

In August 2022, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, acquired TeneoTwo Inc. for an undisclosed amount. This acquisition will broaden, diversify, and strengthen AstraZeneca’s product portfolio by adding oncology drugs and a pipeline phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma. TeneoTwo Inc. is a US-based biotechnology company focusing on medicine development for oncology, including NHL.

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non-Hodgkin lymphoma (NHL) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the non-Hodgkin lymphoma (NHL) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The non-Hodgkin lymphoma market includes revenues earned by entities by treating aggressive lymphomas, indolent lymphomas, Burkitt lymphoma, lymphoma and leukemia, and B-cell lymphomas. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The non-Hodgkin lymphoma market research report is one of a series of new reports from The Business Research Company that provides non-Hodgkin lymphoma market statistics, including non-Hodgkin lymphoma industry global market size, regional shares, competitors with a non-Hodgkin lymphoma market share, detailed non-Hodgkin lymphoma market segments, market trends and opportunities, and any further data you may need to thrive in the non-Hodgkin lymphoma industry. This non-Hodgkin lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non Hodgkin Lymphoma (NHL) Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $10.23 billion
Revenue Forecast In 2033 $14.13 billion
Growth Rate CAGR of 8.4% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Type: B-Cell Lymphoma, T-Cell Lymphoma
2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Bayer AG; Teva Pharmaceutical Industries Ltd.; F. Hoffmann La Roche Ltd.; Merck & Co. Inc.; Eli Lilly and Co.; Novartis AG; GlaxoSmithKline plc; AbbVie Inc.; AstraZeneca plc; Takeda Pharmaceutical Company Limited; Bristol Myers Squibb Co.; Pfizer Inc.; Celgene Corporation; Sanofi S.A.; Janssen Pharmaceuticals Inc.; Johnson & Johnson; Biogen Idec; Boehringer Ingelheim GmbH; Eisai Co. Ltd.; Gilead Sciences; Incyte Corporation; Karyopharm Therapeutics; Kite Pharma Inc.; Kyowa Hakko Kirin Co. Ltd.; MorphoSys AG; Nordic Nanovector ASA; Ono Pharmaceutical Co. Ltd.; Seattle Genetics Inc.; Spectrum Pharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Non Hodgkin Lymphoma (NHL) Market Characteristics

    3. Non Hodgkin Lymphoma (NHL) Market Trends And Strategies

    4. Non Hodgkin Lymphoma (NHL) Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Non Hodgkin Lymphoma (NHL) Market Size and Growth

    5.1. Global Non Hodgkin Lymphoma (NHL) Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Non Hodgkin Lymphoma (NHL) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Non Hodgkin Lymphoma (NHL) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Non Hodgkin Lymphoma (NHL) Market Segmentation

    6.1. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    B-Cell Lymphoma

    T-Cell Lymphoma

    6.2. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Surgery

    Stem Cell Transplant

    Chemotherapy

    Immunotherapy

    Targeted Therapy

    Radiation Therapy

    6.3. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral

    Parenteral

    Other Routes of Administration

    6.4. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    Other Distribution Channels

    6.5. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Homecare

    Specialty Centers

    Other End Users

    7. Non Hodgkin Lymphoma (NHL) Market Regional And Country Analysis

    7.1. Global Non Hodgkin Lymphoma (NHL) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Non Hodgkin Lymphoma (NHL) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market

    8.1. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Non Hodgkin Lymphoma (NHL) Market

    9.1. China Non Hodgkin Lymphoma (NHL) Market Overview

    9.2. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Non Hodgkin Lymphoma (NHL) Market

    10.1. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Non Hodgkin Lymphoma (NHL) Market

    11.1. Japan Non Hodgkin Lymphoma (NHL) Market Overview

    11.2. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Non Hodgkin Lymphoma (NHL) Market

    12.1. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Non Hodgkin Lymphoma (NHL) Market

    13.1. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Non Hodgkin Lymphoma (NHL) Market

    14.1. South Korea Non Hodgkin Lymphoma (NHL) Market Overview

    14.2. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Non Hodgkin Lymphoma (NHL) Market

    15.1. Western Europe Non Hodgkin Lymphoma (NHL) Market Overview

    15.2. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Non Hodgkin Lymphoma (NHL) Market

    16.1. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Non Hodgkin Lymphoma (NHL) Market

    17.1. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Non Hodgkin Lymphoma (NHL) Market

    18.5. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Non Hodgkin Lymphoma (NHL) Market

    19.9. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Non Hodgkin Lymphoma (NHL) Market

    20.13. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Non Hodgkin Lymphoma (NHL) Market

    21.1. Eastern Europe Non Hodgkin Lymphoma (NHL) Market Overview

    21.2. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Non Hodgkin Lymphoma (NHL) Market

    22.1. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Non Hodgkin Lymphoma (NHL) Market

    23.1. North America Non Hodgkin Lymphoma (NHL) Market Overview

    23.2. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Non Hodgkin Lymphoma (NHL) Market

    24.1. USA Non Hodgkin Lymphoma (NHL) Market Overview

    24.2. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Non Hodgkin Lymphoma (NHL) Market

    25.1. Canada Non Hodgkin Lymphoma (NHL) Market Overview

    25.2. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Non Hodgkin Lymphoma (NHL) Market

    26.1. South America Non Hodgkin Lymphoma (NHL) Market Overview

    26.2. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Non Hodgkin Lymphoma (NHL) Market

    27.1. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Non Hodgkin Lymphoma (NHL) Market

    28.1. Middle East Non Hodgkin Lymphoma (NHL) Market Overview

    28.2. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Non Hodgkin Lymphoma (NHL) Market

    29.1. Africa Non Hodgkin Lymphoma (NHL) Market Overview

    29.2. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Non Hodgkin Lymphoma (NHL) Market Competitive Landscape And Company Profiles

    30.1. Non Hodgkin Lymphoma (NHL) Market Competitive Landscape

    30.2. Non Hodgkin Lymphoma (NHL) Market Company Profiles

    30.2.1. Bayer AG

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Teva Pharmaceutical Industries Ltd.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. F. Hoffmann La Roche Ltd.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Merck & Co. Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Eli Lilly and Co.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Non Hodgkin Lymphoma (NHL) Market Competitive Benchmarking

    32. Global Non Hodgkin Lymphoma (NHL) Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Non Hodgkin Lymphoma (NHL) Market

    34. Non Hodgkin Lymphoma (NHL) Market Future Outlook and Potential Analysis

    34.1 Non Hodgkin Lymphoma (NHL) Market In 2028 - Countries Offering Most New Opportunities

    34.2 Non Hodgkin Lymphoma (NHL) Market In 2028 - Segments Offering Most New Opportunities

    34.3 Non Hodgkin Lymphoma (NHL) Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Non Hodgkin Lymphoma (NHL) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Global Non Hodgkin Lymphoma (NHL) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: Asia-Pacific, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: China, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: India, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Japan, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Australia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: Indonesia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: South Korea, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: Western Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: UK, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: Germany, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: France, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Italy, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Spain, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Eastern Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: Russia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: North America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: USA, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: Canada, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: South America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Brazil, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Middle East, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: Africa, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 76: Bayer AG Financial Performance
  • Table 77: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Table 78: F. Hoffmann La Roche Ltd. Financial Performance
  • Table 79: Merck & Co. Inc. Financial Performance
  • Table 80: Eli Lilly and Co. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Non Hodgkin Lymphoma (NHL) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Global Non Hodgkin Lymphoma (NHL) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: Asia-Pacific, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: China, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: India, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Japan, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Australia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: Indonesia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: South Korea, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: Western Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: UK, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: Germany, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: France, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Italy, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Spain, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Eastern Europe, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: Russia, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: North America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: USA, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: Canada, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: South America, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Brazil, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Middle East, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: Africa, Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 76: Bayer AG Financial Performance
  • Figure 77: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Figure 78: F. Hoffmann La Roche Ltd. Financial Performance
  • Figure 79: Merck & Co. Inc. Financial Performance
  • Figure 80: Eli Lilly and Co. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report